EN DE

3SBio Inc (1530) Fair Value & Analysis

Healthcare · HK · Market cap HK$45.7B (≈ $5.8B) · ISIN KYG8875G1029

What is 3SBio Inc really worth?

3I 3SBio Inc 1530 · HK
PriceHK$16.24
Fair ValueHK$76.20
Upside+369.2%
Quality87/100

A strong business, trading 79% below our fair value of HK$76.20.

As of Sep 3, 2026, the fair value of 3SBio Inc is HK$76.20 per share against a price of HK$16.24, so the fair value sits 369% above the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch 3SBio Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +25.9 %/yr)
✓Highly profitable · 47.9% net margin
✓Low debt · generates free cash flow
✓Ranks above peers (12/14)
✓Wide moat 94/100

Risks

!The models disagree: range HK$58.12 to HK$175.57

For context

·1.54% dividend yield
Evidence: High Range HK$58.12 – HK$175.57

Fair value as of: Sep 3, 2026

From 26 valuation models · updated 3 days ago

Fair value updated Sep 3, 2026, revised from HK$76.02 to HK$76.20 (+0.2%) since Aug 13, 2026. Share price −5.7% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The rarer combination: high quality (87/100) AND below fair value. That earns a closer look rather than a quick verdict.
  • The price is below even our cautious bear case (HK$58.12). The market is more pessimistic than our downside scenario.
  • The model range is unusually wide (HK$58.12 to HK$175.57). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Price vs Fair Value (5 years)

HK$35.90 HK$4.38 Fair Value HK$76.20 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 3, 2026.

How to read this chart

60‑month range HK$4.38 – HK$35.90 · fair‑value band HK$58.12 – HK$175.57 · the HK$16.24 price screens below the HK$76.20 fair value. Dashed = 300-day average. As of Sep 3, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

3SBio Inc (1530) currently trades at HK$16.24, while our model-based Fair Value estimate is HK$76.20, implying the stock looks roughly 78.7% undervalued today. The Quality Score stands at 87/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$115.83 per share, and 23 of the 26 models we run sit above the HK$16.24 price. Bear case: the Economic Profit group reads lowest at HK$41.65, and 3 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, 3SBio Inc generated revenue of HK$17.7B at a net margin of 47.9%. Revenue grew 182.7% year over year. It earns a return on equity of 37.5%. The balance sheet holds a net cash position of HK$9.7B. Fundamentals as of Sep 3, 2026

Our scenario range runs from HK$58.12 (bear case) to HK$175.57 (bull case); at HK$16.24, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 56% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at 369%, 1530 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$0.2115 per share, which is 0.4 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$66.09 HK$101.34 HK$213.58 76
Growth DCF HK$62.44 HK$112.16 HK$212.65 75
EPV HK$38.52 HK$44.17 HK$49.11 74
All 26 models by family
DCF Models
FCF DCF HK$66.09 HK$101.34 HK$213.58 76
Owner Earnings HK$57.83 HK$125.70 HK$268.16 71
5Y Revenue Exit HK$33.49 HK$48.78 HK$80.31 71
5Y EBITDA Exit HK$56.59 HK$95.51 HK$171.77 72
5Y P/E Exit HK$63.74 HK$136.30 HK$235.12 68
10Y Revenue Exit HK$42.78 HK$74.94 HK$91.18 67
10Y EBITDA Exit HK$60.32 HK$124.70 HK$235.67 64
10Y P/E Exit HK$65.53 HK$140.09 HK$262.50 60
Earnings-Based
Graham-Dodd HK$23.07 HK$160.92 HK$225.82 63
Lynch FV HK$62.94 HK$89.92 HK$116.90 61
PEG = 1.0 HK$62.94 HK$89.92 HK$116.90 57
EPV HK$38.52 HK$44.17 HK$49.11 74
Dividend Discount
Gordon GGM HK$2.06 HK$4.28 HK$6.78 66
DDM Multi-Stage HK$2.06 HK$3.61 HK$4.49 66
Multiples
P/E Multiple HK$55.99 HK$74.65 HK$93.31 63
P/S Multiple HK$18.58 HK$24.78 HK$30.97 58
P/B Multiple HK$36.75 HK$49.00 HK$61.25 55
EV/EBIT HK$58.42 HK$76.35 HK$94.28 66
EV/EBITDA HK$51.16 HK$66.67 HK$82.17 67
EV/Revenue HK$19.50 HK$25.87 HK$32.25 54
Asset-Based
NCAV (Graham) HK$5.44 HK$7.30 HK$10.89 54
Growth DCF
Growth DCF HK$62.44 HK$112.16 HK$212.65 75
Rev-Margin DCF HK$33.95 HK$55.24 HK$94.00 70
Economic Profit
Residual Income HK$26.72 HK$41.65 HK$503.82 64
ROIC Compounder HK$45.27 HK$60.65 HK$80.75 72
Growth Earnings
Growth-Adj P/E HK$81.08 HK$115.83 HK$150.57 67

Widest divergence: Growth Earnings (HK$115.83) versus Dividend Discount (HK$3.61). Highest evidence: FCF DCF (76).

Notify me when 1530 reaches fair value

Put 1530 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 4.6 as of Jul 2, 2026
P/S ratio 2.22 P/E × margin
EPS (TTM) HK$0.5600 price ÷ EPS = P/E 4.6
Dividend yield 1.5% payout 44.6%
Net margin 47.9% FY2025
Return on equity 37.5% TTM
More key figures
Profitability
Return on assets (EBIT) 13.9% avg 5y
Operating margin 69.2% TTM
Growth
Revenue (TTM) HK$17.7B TTM
Revenue growth (YoY) +183% 3y avg +37.1%
EPS growth (YoY) +612%
Balance sheet & cash flow
Free cash flow HK$9.1B FY2025
Net cash HK$9.7B FY2025

Figures from reported company fundamentals · as of Sep 3, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 87/100

Of which business quality 85 · Market factors (momentum, volatility) 26

Profitability 82
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 85
Earnings quality: real cash, not paper profit
Fin. Strength 99
Balance sheet, leverage, solvency risk
Investment 35
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 90
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally.

Full company description

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and the reduction of allogeneic blood transfusion in surgery patients; and Yisaipu, a TNF-a inhibitor product for rheumatoid arthritis, ankylosing spondylitis, and psoriasis indications. In addition, the company offers Cipterbin, an anti-HER2 mAb for treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; and Mandi, a minoxidil tincture for androgenetic alopecia and alopecia areata. Further, it develops 608, an anti-IL-17A mAb; SSS20 for patients with ITP and severe Aplastic Anemia; SSS06 for the treatment of adult dialysis patients undergoing erythropoietin therapy with a biweekly dosing interval; 613, for the treatment of acute gouty arthritis; 611, an anti-IL-4R a mAb; and 601A, an anti-VEGF mAb. Additionally, the company is involved in manufacture and sale of pharmaceutical drugs; business management; provision of technical services, investment advisory services, financial services, sports services, clinic services, technology services, and agricultural services; retail of pharmaceuticals; and enterprise management consulting. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3SBio Inc reported revenue of 17.7B CNY in FY2025 versus 6.4B CNY in FY2021, a compound +29.0%/yr. Reported net income was 8.5B CNY in FY2025, compounding +50.5%/yr from FY2021.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$17.7B
Latest YoY
+94.3%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+37.1%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+25.9%
Avg. revenue growth/yr (19Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+29.6%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
≈ +56.6% (approximate, leans on 2025) · in HKD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+55.1%
Dividend yield1.5%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 55.1% vs 10Y 31.1%, picking up
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26.2% (2020) → 59.6% (2025) · rising
Worst earnings drop77% (2014) · in HKD
⚠ Rate leans on 2025: that final year sits 376% above its own trend (e.g. a one-off disposal gain) and could not be adjusted
Revenue +29.0%/yr
FY21 6.4B CNY
FY22 6.9B CNY
FY23 7.8B CNY
FY24 9.1B CNY
FY25 17.7B CNY
Net income +50.5%/yr
FY21 1.7B CNY
FY22 1.9B CNY
FY23 1.5B CNY
FY24 2.1B CNY
FY25 8.5B CNY
Character of growth · EPS growth decomposed (2014-2025) +24.7 % p.a.
Revenue per share +21.3 %

of which total revenue +22.4 % · buybacks/dilution −0.9 %

EBIT margin +4.1 %
Tax rate −0.3 %
Residual (interest, one-offs) −0.9 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

Watch 1530: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

3SBio Inc · Fair Value
HK$76.20 +79%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "3SBio Inc Fair Value". https://www.fairvalue-calculator.com/stock/1530.HK

Peer Group

Biotechnology · 627 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 87 · Top 25%
Return on equity (TTM) 38% · Top 25%
Return on assets 22% · Top 25%
Net margin (TTM) 48% · Top 25%
Operating margin (TTM) 69% · Top 25%
Revenue growth 183% · Top 25%
Dividend yield (TTM) 1.5% · Above median
Debt / equity 0.03× · Lower than median

Valuation Multiples vs Biotechnology median · lower = cheaper

P/E (TTM) 4.6× · Cheaper than 75% of peers
P/B 1.68× · Pricier than median
P/S (TTM) 2.59× · Cheaper than median
P/FCF 0.6× · Cheaper than 75% of peers
EV/EBITDA 3.1× · Cheaper than 75% of peers
PEG 2.83× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 0
PAST100 · sector 0
HEALTH99 · sector 98
DIVIDEND31 · sector 26

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 3, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $547.55 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $807.71 $594.40 −26%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,518,000 KRW 1,055,793 KRW −30%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%
Incyte Corporation INCY $123.22 $115.79 −6%

Compare 3SBio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is 3SBio Inc (1530) overvalued or undervalued?
As of Sep 3, 2026, our model estimates a fair value of HK$76.20 versus a price of HK$16.24, about +369% upside (undervalued).
What is the fair value of 1530?
Our model-based fair value for 3SBio Inc is HK$76.20 (as of Sep 3, 2026), built from audited fundamentals. The current price: HK$16.24.
What is the quality score of 1530?
3SBio Inc has a Quality Score of 87/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 3SBio Inc (1530)?
Our model-based price target is the fair value of HK$76.20 (as of Sep 3, 2026) from 26 valuation models. Cautious scenario HK$58.12, optimistic scenario HK$175.57. It is a calculation from audited fundamentals, not an analyst target.
What is the 3SBio Inc stock forecast for 2026?
Our models put fair value at HK$76.20, about +369% upside versus a price of HK$16.24 (undervalued). Cautious scenario HK$58.12, optimistic scenario HK$175.57. The calculation is refreshed regularly with new filings.
What is the revenue of 3SBio Inc (1530)?
3SBio Inc reported trailing-twelve-month revenue of about HK$17.7B (latest available figure, as of Sep 3, 2026).
What is the net profit margin of 1530?
The net profit margin of 3SBio Inc is about 47.9%, meaning it keeps roughly 47.9% of revenue as net income. Based on the latest reported figures.
Does 3SBio Inc pay a dividend?
3SBio Inc currently shows a dividend yield of about 1.54% relative to its recent price (as of Sep 3, 2026).
Free · no account needed

Watch 3SBio Inc in the live analysis

One click puts 3SBio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.